Hemoglobinopathies Market – By Disease Type, By Treatment, By End Use – Global Forecast, 2024 – 2032

Key players in the hemoglobinopathies industry include bluebird bio, Bristol-Myers Squibb Company, CHIESI FARMACEUTICI, Emmaus Medical, Medunik USA, Novartis, Pfizer, and Prolong Pharmaceuticals.

The North American hemoglobinopathies industry is expected to grow at a 10% CAGR, reaching USD 5.7 billion by 2032, driven by increased awareness, early diagnosis, and advanced treatment options.

The sickle cell disease segment dominated the market with USD 3.3 billion in 2023, supported by therapies such as blood transfusions, pain management drugs, and emerging treatments like gene therapy.

The global hemoglobinopathies industry was valued at USD 6.3 billion in 2023 and is projected to grow at a 10.4% CAGR from 2024 to 2032, driven by the rising global prevalence of hemoglobin-related disorders.